findmyKOL
Clinical trialNCT03842228Active, not recruitingPhase 1Interventional

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

SponsorNational Cancer Institute (NCI)Enrollment39Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Keck Medicine of Usc Buena Park

    Buena Park, California, United States

  • Keck Medicine of Usc Koreatown

    Los Angeles, California, United States

  • Los Angeles General Medical Center

    Los Angeles, California, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Usc Norris Oncology/hematology-Newport Beach

    Newport Beach, California, United States

  • Keck Medical Center of Usc Pasadena

    Pasadena, California, United States

  • Uchealth University of Colorado Hospital

    Aurora, Colorado, United States

  • Northwestern University

    Chicago, Illinois, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • University of Texas at Austin

    Austin, Texas, United States

  • University of Texas Medical Branch

    Galveston, Texas, United States

  • Ut Md Anderson Cancer Center

    Houston, Texas, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Nov 2019
Primary completion
29 Jul 2024
Completion
31 Dec 2026
Last update posted
17 Jun 2026
Registered enrollment
39
Registry id
NCT03842228

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.